Despite the threat of a 200% tariff, most pharma stocks remained stable. US President Donald Trump’s 200% tariff threat on the pharmaceutical industry is a “shock” that will reverberate through global ...

Niagen has secured a worldwide exclusive commercial licence agreement with Haukeland University Hospital to treat Parkinson's disease.

JCR Pharmaceuticals has signed a licence agreement with Alexion, AstraZeneca Rare Disease, for its proprietary JUST-AAV capsids.

Global funding cuts, including those made by the Trump administration, are set to increase cases of HIV in Africa, research suggests.

Swissmedic approved the registration of IFINWIL (eflornithine) as a monotherapy to treat paediatric patients with high-risk neuroblastoma, ...

Biocon Biologics CEO and managing director Shreehas Tambe stated: “The approval of Vevzuo and Evfraxy in Europe underscores our strong scientific expertise and commitment to expanding patient access ...

Ligand Pharmaceuticals’ wholly owned subsidiary LNHC has concluded its merger with Channel Therapeutics’ CHRO Merger Sub, resulting in the formation of a new entity, Pelthos Therapeutics (PTHS). In ...